{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:02:24Z","timestamp":1790100144917,"version":"4.0.1"},"posted":{"date-parts":[[2025,12,3]]},"group-title":"In Review","reference-count":63,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,11,20]]},"abstract":"<title>Abstract<\/title>\n                <p>Tau pathology, characterized by the aberrant aggregation and accumulation of tau in neurons and glial cells, plays a critical role in the onset and progression of multiple neurodegenerative diseases. Although synucleinopathies such as Parkinson\u2019s disease (PD) and dementia with Lewy bodies (DLB) are primarily defined by intracytoplasmic inclusions of \u03b1-Synuclein (\u03b1-Syn), they frequently exhibit substantial tau co-pathology. Emerging genetic and pathological evidence suggests a mechanistic interplay between \u03b1-Syn and tau that amplifies their aggregation and accelerates neurodegeneration. In this study, we systematically investigated the temporal progression of tau pathology in a transgenic PD mouse model that overexpresses human wild-type (WT) \u03b1-Syn (hSyn mice). Prior work has shown that this model develops \u03b1-Syn pathology across key brain regions, including the substantia nigra, cortex, hippocampus, and striatum, accompanied by microglial activation and synaptic dysfunction. Using a combination of biochemical, biophysical, and immunological approaches, we demonstrate a progressive accumulation of hyperphosphorylated tau, as well as soluble and insoluble tau aggregates, in the brains of hSyn mice. Electron microscopy of insoluble fractions reveals abundant fibrillar structures, while mass spectrometry confirms that these fibrils consist of both \u03b1-Syn and tau. Notably, these pathologies are absent in WT littermates, suggesting that tau aggregation arises as a consequence of \u03b1-Syn overexpression rather than normal aging. Collectively, our findings establish a mechanistic link between \u03b1-Syn and tau aggregation, identifying tau as an active contributor to \u03b1-Syn\u2013driven neurodegeneration. This study provides direct experimental evidence that tau co-pathology contributes to disease progression in synucleinopathies, underscoring the therapeutic potential of targeting pathological tau to mitigate neurodegeneration in PD, DLB, and related disorders.<\/p>","DOI":"10.21203\/rs.3.rs-8166445\/v1","type":"posted-content","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T16:32:00Z","timestamp":1764779520000},"source":"Crossref","is-referenced-by-count":1,"title":["Human Wild-Type \u03b1-Synuclein Drives Progressive Tau Pathology in a Disease-Relevant Mouse Model of Synucleinopathy"],"prefix":"10.21203","author":[{"given":"Sudipta","family":"Senapati","sequence":"first","affiliation":[{"name":"University of Texas Medical Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Sciortino","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Samples","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Shchankin","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Zhao","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Montalbano","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakez","family":"Kayed","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","first-page":"133","article-title":"Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues","author":"Samudra N","year":"2023","unstructured":"Samudra N, Lane-Donovan C, VandeVrede L, Boxer AL: Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues. J Clin Invest 2023, 133.","journal-title":"J Clin Invest"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13024-021-00476-x","article-title":"Cellular and pathological heterogeneity of primary tauopathies","volume":"16","author":"Chung DC","year":"2021","unstructured":"Chung DC, Roemer S, Petrucelli L, Dickson DW: Cellular and pathological heterogeneity of primary tauopathies. Mol Neurodegener 2021, 16:57.","journal-title":"Mol Neurodegener"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/alz.13490","article-title":"Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies","volume":"20","author":"Gaikwad S","year":"2024","unstructured":"Gaikwad S, Senapati S, Haque MA, Kayed R: Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies. Alzheimers Dement 2024, 20:709\u2013727.","journal-title":"Alzheimers Dement"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-1326-4-13","article-title":"The role of tau in neurodegeneration","volume":"4","author":"Gendron TF","year":"2009","unstructured":"Gendron TF, Petrucelli L: The role of tau in neurodegeneration. Molecular Neurodegeneration 2009, 4:13.","journal-title":"Molecular Neurodegeneration"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41580-024-00753-9","article-title":"Cellular and pathological functions of tau","volume":"25","author":"Parra Bravo C","year":"2024","unstructured":"Parra Bravo C, Naguib SA, Gan L: Cellular and pathological functions of tau. Nat Rev Mol Cell Biol 2024, 25:845\u2013864.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40035-024-00429-6","article-title":"Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies","volume":"13","author":"Zhang X","year":"2024","unstructured":"Zhang X, Wang J, Zhang Z, Ye K: Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies. Translational Neurodegeneration 2024, 13:40.","journal-title":"Translational Neurodegeneration"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"595532","DOI":"10.3389\/fneur.2020.595532","article-title":"Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation","volume":"11","author":"Alquezar C","year":"2020","unstructured":"Alquezar C, Arya S, Kao AW: Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation. Front Neurol 2020, 11:595532.","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e13112","DOI":"10.1111\/bpa.13112","article-title":"Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer's disease, progressive supranuclear palsy, and dementia with Lewy bodies","volume":"33","author":"Montalbano M","year":"2023","unstructured":"Montalbano M, Majmundar L, Sengupta U, Fung L, Kayed R: Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer's disease, progressive supranuclear palsy, and dementia with Lewy bodies. Brain Pathol 2023, 33:e13112.","journal-title":"Brain Pathol"},{"key":"ref9","author":"Alavi Naini SM","year":"2015","unstructured":"Alavi Naini SM, Soussi-Yanicostas N: Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies? Oxid Med Cell Longev 2015, 2015:151979."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40035-021-00270-1","article-title":"The role of pathological tau in synaptic dysfunction in Alzheimer's diseases","volume":"10","author":"Wu M","year":"2021","unstructured":"Wu M, Zhang M, Yin X, Chen K, Hu Z, Zhou Q, Cao X, Chen Z, Liu D: The role of pathological tau in synaptic dysfunction in Alzheimer's diseases. Transl Neurodegener 2021, 10:45.","journal-title":"Transl Neurodegener"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40035-024-00407-y","article-title":"Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration","volume":"13","author":"Li W","year":"2024","unstructured":"Li W, Li J-Y: Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration. Translational Neurodegeneration 2024, 13:16.","journal-title":"Translational Neurodegeneration"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"102270","DOI":"10.1016\/j.pneurobio.2022.102270","article-title":"Amyloid \u03b2, Tau, and \u03b1-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases","volume":"214","author":"Sengupta U","year":"2022","unstructured":"Sengupta U, Kayed R: Amyloid \u03b2, Tau, and \u03b1-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Progress in Neurobiology 2022, 214:102270.","journal-title":"Progress in Neurobiology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4103\/1673-5374.382231","article-title":"Pathological and physiological functional cross-talks of \u03b1-synuclein and tau in the central nervous system","volume":"19","author":"Jin M","year":"2024","unstructured":"Jin M, Wang S, Gao X, Zou Z, Hirotsune S, Sun L: Pathological and physiological functional cross-talks of \u03b1-synuclein and tau in the central nervous system. Neural Regen Res 2024, 19:855\u2013862.","journal-title":"Neural Regen Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.biopsych.2014.12.019","article-title":"Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies","volume":"78","author":"Sengupta U","year":"2015","unstructured":"Sengupta U, Guerrero-Mu\u00f1oz MJ, Castillo-Carranza DL, Lasagna-Reeves CA, Gerson JE, Paulucci-Holthauzen AA, Krishnamurthy S, Farhed M, Jackson GR, Kayed R: Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol Psychiatry 2015, 78:672\u2013683.","journal-title":"Biol Psychiatry"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","article-title":"\u03b1-synuclein in the pathophysiology of Alzheimer\u2019s disease","volume":"14","author":"Twohig D","year":"2019","unstructured":"Twohig D, Nielsen HM: \u03b1-synuclein in the pathophysiology of Alzheimer\u2019s disease. Molecular Neurodegeneration 2019, 14:23.","journal-title":"Molecular Neurodegeneration"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jnen\/62.4.389","article-title":"Colocalization of Tau and Alpha-Synuclein Epitopes in Lewy Bodies","volume":"62","author":"Ishizawa T","year":"2003","unstructured":"Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW: Colocalization of Tau and Alpha-Synuclein Epitopes in Lewy Bodies. Journal of Neuropathology & Experimental Neurology 2003, 62:389\u2013397.","journal-title":"Journal of Neuropathology & Experimental Neurology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40478-024-01913-w","article-title":"Distinct subcellular localization of tau and alpha-synuclein in lewy body disease","volume":"13","author":"Fischer DL","year":"2025","unstructured":"Fischer DL, Menard M, Abdelaziz OZ, Kanaan NM, Cobbs VG, Kennedy RE, Serrano GE, Beach TG, Volpicelli-Daley LA: Distinct subcellular localization of tau and alpha-synuclein in lewy body disease. Acta Neuropathologica Communications 2025, 13:14.","journal-title":"Acta Neuropathologica Communications"},{"key":"ref18","first-page":"218","article-title":"Lee VM: \u03b1-Synuclein modulates tau spreading in mouse brains","author":"Bassil F","year":"2021","unstructured":"Bassil F, Meymand ES, Brown HJ, Xu H, Cox TO, Pattabhiraman S, Maghames CM, Wu Q, Zhang B, Trojanowski JQ, Lee VM: \u03b1-Synuclein modulates tau spreading in mouse brains. J Exp Med 2021, 218.","journal-title":"J Exp Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13024-025-00822-3","article-title":"Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer's disease","volume":"20","author":"Franzmeier N","year":"2025","unstructured":"Franzmeier N, Roemer-Cassiano SN, Bernhardt AM, Dehsarvi A, Dewenter A, Steward A, Biel D, Frontzkowski L, Zhu Z, Gn\u00f6rich J, et al: Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer's disease. Mol Neurodegener 2025, 20:31.","journal-title":"Mol Neurodegener"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.biopsych.2017.12.018","article-title":"\u03b1-Synuclein Oligomers Induce a Unique Toxic Tau Strain","volume":"84","author":"Castillo-Carranza DL","year":"2018","unstructured":"Castillo-Carranza DL, Guerrero-Mu\u00f1oz MJ, Sengupta U, Gerson JE, Kayed R: \u03b1-Synuclein Oligomers Induce a Unique Toxic Tau Strain. Biological Psychiatry 2018, 84:499\u2013508.","journal-title":"Biological Psychiatry"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"fcaa090","DOI":"10.1093\/braincomms\/fcaa090","article-title":"Differential cross-seeding properties of tau and \u03b1-synuclein in mouse models of tauopathy and synucleinopathy","volume":"2","author":"Williams T","year":"2020","unstructured":"Williams T, Sorrentino Z, Weinrich M, Giasson BI, Chakrabarty P: Differential cross-seeding properties of tau and \u03b1-synuclein in mouse models of tauopathy and synucleinopathy. Brain Commun 2020, 2:fcaa090.","journal-title":"Brain Commun"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-2202-12-79","article-title":"Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease","volume":"12","author":"Kaul T","year":"2011","unstructured":"Kaul T, Credle J, Haggerty T, Oaks AW, Masliah E, Sidhu A: Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease. BMC Neuroscience 2011, 12:79.","journal-title":"BMC Neuroscience"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1096\/fj.06-6092com","article-title":"Alpha-Synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism","volume":"20","author":"Duka T","year":"2006","unstructured":"Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL, Sidhu A: Alpha-Synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism. The FASEB Journal 2006, 20:2302\u20132312.","journal-title":"The FASEB Journal"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40035-022-00309-x","article-title":"Loss of tau expression attenuates neurodegeneration associated with \u03b1-synucleinopathy","volume":"11","author":"Vermilyea SC","year":"2022","unstructured":"Vermilyea SC, Christensen A, Meints J, Singh B, Martell-Mart\u00ednez H, Karim MR, Lee MK: Loss of tau expression attenuates neurodegeneration associated with \u03b1-synucleinopathy. Translational Neurodegeneration 2022, 11:34.","journal-title":"Translational Neurodegeneration"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.expneurol.2004.07.016","article-title":"Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein","volume":"192","author":"Frasier M","year":"2005","unstructured":"Frasier M, Walzer M, McCarthy L, Magnuson D, Lee JM, Haas C, Kahle P, Wolozin B: Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp Neurol 2005, 192:274\u2013287.","journal-title":"Exp Neurol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e17953","DOI":"10.1371\/journal.pone.0017953","article-title":"Tauopathic Changes in the Striatum of A53T \u03b1-Synuclein Mutant Mouse Model of Parkinson's Disease","volume":"6","author":"Wills J","year":"2011","unstructured":"Wills J, Credle J, Haggerty T, Lee J-H, Oaks AW, Sidhu A: Tauopathic Changes in the Striatum of A53T \u03b1-Synuclein Mutant Mouse Model of Parkinson's Disease. PLOS ONE 2011, 6:e17953.","journal-title":"PLOS ONE"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"35104","DOI":"10.1074\/jbc.M111.247965","article-title":"E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment","volume":"286","author":"Emmer KL","year":"2011","unstructured":"Emmer KL, Waxman EA, Covy JP, Giasson BI: E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem 2011, 286:35104\u201335118.","journal-title":"J Biol Chem"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"9754","DOI":"10.1523\/JNEUROSCI.0344-18.2018","article-title":"A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes","volume":"38","author":"Teravskis PJ","year":"2018","unstructured":"Teravskis PJ, Covelo A, Miller EC, Singh B, Martell-Mart\u00ednez HA, Benneyworth MA, Gallardo C, Oxnard BR, Araque A, Lee MK, Liao D: A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes. The Journal of Neuroscience 2018, 38:9754\u20139767.","journal-title":"The Journal of Neuroscience"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1096\/fj.08-120410","article-title":"Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models","volume":"23","author":"Duka T","year":"2009","unstructured":"Duka T, Duka V, Joyce JN, Sidhu A: Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. Faseb j 2009, 23:2820\u20132830.","journal-title":"Faseb j"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00401-019-02032-w","article-title":"Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of \u03b1-synucleinopathy","volume":"138","author":"Singh B","year":"2019","unstructured":"Singh B, Covelo A, Martell-Mart\u00ednez H, Nanclares C, Sherman MA, Okematti E, Meints J, Teravskis PJ, Gallardo C, Savonenko AV, et al: Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of \u03b1-synucleinopathy. Acta Neuropathologica 2019, 138:551\u2013574.","journal-title":"Acta Neuropathologica"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41531-023-00568-z","article-title":"Linking environmental risk factors with epigenetic mechanisms in Parkinson's disease","volume":"9","author":"Tsalenchuk M","year":"2023","unstructured":"Tsalenchuk M, Gentleman SM, Marzi SJ: Linking environmental risk factors with epigenetic mechanisms in Parkinson's disease. NPJ Parkinsons Dis 2023, 9:123.","journal-title":"NPJ Parkinsons Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41531-020-0110-8","article-title":"Genetic predispositions of Parkinson\u2019s disease revealed in patient-derived brain cells","volume":"6","author":"Tran J","year":"2020","unstructured":"Tran J, Anastacio H, Bardy C: Genetic predispositions of Parkinson\u2019s disease revealed in patient-derived brain cells. npj Parkinson's Disease 2020, 6:8.","journal-title":"npj Parkinson's Disease"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/bmb\/ldad035","article-title":"Genetics in Parkinson's disease, state-of-the-art and future perspectives","volume":"149","author":"Trevisan L","year":"2024","unstructured":"Trevisan L, Gaudio A, Monfrini E, Avanzino L, Di Fonzo A, Mandich P: Genetics in Parkinson's disease, state-of-the-art and future perspectives. Br Med Bull 2024, 149:60\u201371.","journal-title":"Br Med Bull"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic Interactions between A\u03b2, Tau, and \u03b1-Synuclein: Acceleration of Neuropathology and Cognitive Decline","volume":"30","author":"Clinton LK","year":"2010","unstructured":"Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM: Synergistic Interactions between A\u03b2, Tau, and \u03b1-Synuclein: Acceleration of Neuropathology and Cognitive Decline. The Journal of Neuroscience 2010, 30:7281\u20137289.","journal-title":"The Journal of Neuroscience"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/WCO.0000000000001173","article-title":"Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers","volume":"36","author":"Gibson LL","year":"2023","unstructured":"Gibson LL, Abdelnour C, Chong J, Ballard C, Aarsland D: Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers. Current Opinion in Neurology 2023, 36:264\u2013275.","journal-title":"Current Opinion in Neurology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/s41467-020-15119-w","article-title":"Microglia clear neuron-released \u03b1-synuclein via selective autophagy and prevent neurodegeneration","volume":"11","author":"Choi I","year":"2020","unstructured":"Choi I, Zhang Y, Seegobin SP, Pruvost M, Wang Q, Purtell K, Zhang B, Yue Z: Microglia clear neuron-released \u03b1-synuclein via selective autophagy and prevent neurodegeneration. Nat Commun 2020, 11:1386.","journal-title":"Nat Commun"},{"key":"ref37","first-page":"15","article-title":"The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models","author":"Polinski NK","year":"2022","unstructured":"Polinski NK, Martinez TN, Ramboz S, Sasner M, Herberth M, Switzer R, Ahmad SO, Pelligrino LJ, Clark SW, Marcus JN, et al: The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models. Dis Model Mech 2022, 15.","journal-title":"Dis Model Mech"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00401-021-02381-5","article-title":"Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric \u03b1-synuclein accumulation in the brain and gut","volume":"143","author":"Nimmo JT","year":"2022","unstructured":"Nimmo JT, Smith H, Wang CY, Teeling JL, Nicoll JAR, Verma A, Dodart JC, Liu Z, Lin F, Carare RO: Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric \u03b1-synuclein accumulation in the brain and gut. Acta Neuropathol 2022, 143:55\u201373.","journal-title":"Acta Neuropathol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/15548627.2021.1937897","article-title":"Piperine promotes autophagy flux by P2RX4 activation in SNCA\/\u03b1-synuclein-induced Parkinson disease model","volume":"18","author":"Li R","year":"2022","unstructured":"Li R, Lu Y, Zhang Q, Liu W, Yang R, Jiao J, Liu J, Gao G, Yang H: Piperine promotes autophagy flux by P2RX4 activation in SNCA\/\u03b1-synuclein-induced Parkinson disease model. Autophagy 2022, 18:559\u2013575.","journal-title":"Autophagy"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1177\/0271678X19895432","article-title":"Reduced cerebral blood flow in an \u03b1-synuclein transgenic mouse model of Parkinson's disease","volume":"40","author":"Biju KC","year":"2020","unstructured":"Biju KC, Shen Q, Hernandez ET, Mader MJ, Clark RA: Reduced cerebral blood flow in an \u03b1-synuclein transgenic mouse model of Parkinson's disease. J Cereb Blood Flow Metab 2020, 40:2441\u20132453.","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3233\/JAD-220518","article-title":"Passive Immunotherapy Targeting Tau Oligomeric Strains Reverses Tauopathy Phenotypes in Aged Human-Tau Mice in a Mouse Model-Specific Manner","volume":"90","author":"Bittar A","year":"2022","unstructured":"Bittar A, Al-Lahham R, Bhatt N, Moore K, Montalbano M, Jerez C, Fung L, McAllen S, Ellsworth A, Kayed R: Passive Immunotherapy Targeting Tau Oligomeric Strains Reverses Tauopathy Phenotypes in Aged Human-Tau Mice in a Mouse Model-Specific Manner. J Alzheimers Dis 2022, 90:1103\u20131122.","journal-title":"J Alzheimers Dis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"102562","DOI":"10.1016\/j.pneurobio.2023.102562","article-title":"Traumatic brain injury derived pathological tau polymorphs induce the distinct propagation pattern and neuroinflammatory response in wild type mice","volume":"232","author":"Puangmalai N","year":"2024","unstructured":"Puangmalai N, Bhatt N, Bittar A, Jerez C, Shchankin N, Kayed R: Traumatic brain injury derived pathological tau polymorphs induce the distinct propagation pattern and neuroinflammatory response in wild type mice. Prog Neurobiol 2024, 232:102562.","journal-title":"Prog Neurobiol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"101766","DOI":"10.1016\/j.jbc.2022.101766","article-title":"Lysine 63-linked ubiquitination of tau oligomers contributes to the pathogenesis of Alzheimer's disease","volume":"298","author":"Puangmalai N","year":"2022","unstructured":"Puangmalai N, Sengupta U, Bhatt N, Gaikwad S, Montalbano M, Bhuyan A, Garcia S, McAllen S, Sonawane M, Jerez C, et al: Lysine 63-linked ubiquitination of tau oligomers contributes to the pathogenesis of Alzheimer's disease. J Biol Chem 2022, 298:101766.","journal-title":"J Biol Chem"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"14807","DOI":"10.1074\/jbc.RA120.014630","article-title":"Modulating disease-relevant tau oligomeric strains by small molecules","volume":"295","author":"Lo Cascio F","year":"2020","unstructured":"Lo Cascio F, Garcia S, Montalbano M, Puangmalai N, McAllen S, Pace A, Palumbo Piccionello A, Kayed R: Modulating disease-relevant tau oligomeric strains by small molecules. J Biol Chem 2020, 295:14807\u201314825.","journal-title":"J Biol Chem"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40478-018-0615-0","article-title":"Formation of Toxic Oligomeric Assemblies of RNA-binding Protein: Musashi in Alzheimer's disease","volume":"6","author":"Sengupta U","year":"2018","unstructured":"Sengupta U, Montalbano M, McAllen S, Minuesa G, Kharas M, Kayed R: Formation of Toxic Oligomeric Assemblies of RNA-binding Protein: Musashi in Alzheimer's disease. Acta Neuropathol Commun 2018, 6:113.","journal-title":"Acta Neuropathol Commun"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s42003-025-07499-w","article-title":"Brain-derived tau oligomer polymorphs: distinct aggregations, stability profiles, and biological activities","volume":"8","author":"Lo Cascio F","year":"2025","unstructured":"Lo Cascio F, Park S, Sengupta U, Puangmalai N, Bhatt N, Shchankin N, Jerez C, Moreno N, Bittar A, Xavier R, et al: Brain-derived tau oligomer polymorphs: distinct aggregations, stability profiles, and biological activities. Communications Biology 2025, 8:53.","journal-title":"Communications Biology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/nbt.1511","article-title":"MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification","volume":"26","author":"Cox J","year":"2008","unstructured":"Cox J, Mann M: MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature Biotechnology 2008, 26:1367\u20131372.","journal-title":"Nature Biotechnology"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1074\/mcp.M113.031591","article-title":"Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ*","volume":"13","author":"Cox J","year":"2014","unstructured":"Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M: Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ*. Molecular & Cellular Proteomics 2014, 13:2513\u20132526.","journal-title":"Molecular & Cellular Proteomics"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nmeth.3901","article-title":"The Perseus computational platform for comprehensive analysis of (prote)omics data","volume":"13","author":"Tyanova S","year":"2016","unstructured":"Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, Mann M, Cox J: The Perseus computational platform for comprehensive analysis of (prote)omics data. Nature Methods 2016, 13:731\u2013740.","journal-title":"Nature Methods"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s12035-020-01913-6","article-title":"Polymorphic \u03b1-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein","volume":"57","author":"Sengupta U","year":"2020","unstructured":"Sengupta U, Puangmalai N, Bhatt N, Garcia S, Zhao Y, Kayed R: Polymorphic \u03b1-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein. Mol Neurobiol 2020, 57:2741\u20132765.","journal-title":"Mol Neurobiol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1373\/clinchem.2013.216515","article-title":"Quantification of Tau in Cerebrospinal Fluid by Immunoaffinity Enrichment and Tandem Mass Spectrometry","volume":"60","author":"McAvoy T","year":"2014","unstructured":"McAvoy T, Lassman ME, Spellman DS, Ke Z, Howell BJ, Wong O, Zhu L, Tanen M, Struyk A, Laterza OF: Quantification of Tau in Cerebrospinal Fluid by Immunoaffinity Enrichment and Tandem Mass Spectrometry. Clinical Chemistry 2014, 60:683\u2013689.","journal-title":"Clinical Chemistry"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"102270","DOI":"10.1016\/j.pneurobio.2022.102270","article-title":"Amyloid \u03b2, Tau, and \u03b1-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases","volume":"214","author":"Sengupta U","year":"2022","unstructured":"Sengupta U, Kayed R: Amyloid \u03b2, Tau, and \u03b1-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Prog Neurobiol 2022, 214:102270.","journal-title":"Prog Neurobiol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s12031-020-01776-5","article-title":"Tau in the Pathophysiology of Parkinson\u2019s Disease","volume":"71","author":"Pan L","year":"2021","unstructured":"Pan L, Meng L, He M, Zhang Z: Tau in the Pathophysiology of Parkinson\u2019s Disease. Journal of Molecular Neuroscience 2021, 71:2179\u20132191.","journal-title":"Journal of Molecular Neuroscience"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.4103\/1673-5374.193234","article-title":"Neurofibrillary tangles in Alzheimer's disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics","volume":"11","author":"Metaxas A","year":"2016","unstructured":"Metaxas A, Kempf SJ: Neurofibrillary tangles in Alzheimer's disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics. Neural Regen Res 2016, 11:1579\u20131581.","journal-title":"Neural Regen Res"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s40478-020-00967-w","article-title":"Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer\u2019s disease and other tauopathies","volume":"8","author":"Xia Y","year":"2020","unstructured":"Xia Y, Prokop S, Gorion K-MM, Kim JD, Sorrentino ZA, Bell BM, Manaois AN, Chakrabarty P, Davies P, Giasson BI: Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer\u2019s disease and other tauopathies. Acta Neuropathologica Communications 2020, 8:88.","journal-title":"Acta Neuropathologica Communications"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3233\/JAD-181263","article-title":"Phospho-Tau Changes in the Human CA1 During Alzheimer's Disease Progression","volume":"69","author":"Regalado-Reyes M","year":"2019","unstructured":"Regalado-Reyes M, Furcila D, Hern\u00e1ndez F, \u00c1vila J, DeFelipe J, Le\u00f3n-Espinosa G: Phospho-Tau Changes in the Human CA1 During Alzheimer's Disease Progression. J Alzheimers Dis 2019, 69:277\u2013288.","journal-title":"J Alzheimers Dis"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/alz.12321","article-title":"Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research","volume":"17","author":"Moloney CM","year":"2021","unstructured":"Moloney CM, Lowe VJ, Murray ME: Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research. Alzheimer's & Dementia 2021, 17:1554\u20131574.","journal-title":"Alzheimer's & Dementia"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/brain\/awad388","article-title":"Nigrostriatal tau pathology in parkinsonism and Parkinson's disease","volume":"147","author":"Chu Y","year":"2024","unstructured":"Chu Y, Hirst WD, Federoff HJ, Harms AS, Stoessl AJ, Kordower JH: Nigrostriatal tau pathology in parkinsonism and Parkinson's disease. Brain 2024, 147:444\u2013457.","journal-title":"Brain"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.expneurol.2010.06.017","article-title":"Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia","volume":"225","author":"Wills J","year":"2010","unstructured":"Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A: Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010, 225:210\u2013218.","journal-title":"Exp Neurol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ana.20723","article-title":"Substantia nigra tangles are related to gait impairment in older persons","volume":"59","author":"Schneider JA","year":"2006","unstructured":"Schneider JA, Li JL, Li Y, Wilson RS, Kordower JH, Bennett DA: Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol 2006, 59:166\u2013173.","journal-title":"Ann Neurol"},{"key":"ref61","author":"Rajput A","year":"2006","unstructured":"Rajput A, Dickson DW, Robinson CA, Ross OA, D\u00e4chsel JC, Lincoln SJ, Cobb SA, Rajput ML, Farrer MJ: Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006, 67:1506\u20131508."},{"key":"ref62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13024-018-0245-9","article-title":"Tau oligomers mediate \u03b1-synuclein toxicity and can be targeted by immunotherapy","volume":"13","author":"Gerson JE","year":"2018","unstructured":"Gerson JE, Farmer KM, Henson N, Castillo-Carranza DL, Carretero Murillo M, Sengupta U, Barrett A, Kayed R: Tau oligomers mediate \u03b1-synuclein toxicity and can be targeted by immunotherapy. Mol Neurodegener 2018, 13:13.","journal-title":"Mol Neurodegener"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1093\/brain\/awac171","article-title":"Tau accelerates \u03b1-synuclein aggregation and spreading in Parkinson's disease","volume":"145","author":"Pan L","year":"2022","unstructured":"Pan L, Li C, Meng L, Tian Y, He M, Yuan X, Zhang G, Zhang Z, Xiong J, Chen G, Zhang Z: Tau accelerates \u03b1-synuclein aggregation and spreading in Parkinson's disease. Brain 2022, 145:3454\u20133471.","journal-title":"Brain"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8166445\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8166445\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:41:29Z","timestamp":1787334089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8166445\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":63,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-8166445\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s44477-026-00033-0","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,12,3]]},"subtype":"preprint"}}